A soluble somatostatin-binding protein was detected in the cytosol fractions of various rat, human and bovine tissues. Maximum binding occurred at pH 8.0-8.5 and was Ca2+-dependent. The specific binding of somatostatin per 10cg of cytosol protein from 12 rat tissues ranged between 36 and 15 %, and 3 % for peripheral blood cells. There was also substantial binding in cytosol from human anterior pituitary and liver, and bovine anterior pituitary. The specific binding in rat and human plasma in the presence of EDTA was only 1 %. Gel filtration suggested a molecular weight of approx. 80000 for the somatostatin-binding protein from several sources. Exposure of the binding protein to trypsin eliminates somatostatin-binding activity but ribonuclease and deoxyribonuclease have no effect. The binding protein is thermolabile, ethanol-precipitable, and not completely specific for somatostatin. Bound 125I-labelled 
Somatostatin inhibits pituitary somatotropin secretion (Brazeau et al., 1973) , but also affects the function of the pancreas (Koerker et al., 1974) , stomach. (Bloom et al., 1974) and brain (Renaud et al., 1975; Cotzias & Papavasiliou, 1976; Havlicek et al., 1976) . Despite many reports about the effects of somatostatin on different organs, the physiological role and mechanism of action of somatostatin is as yet unknown. It is widely assumed that the first interaction between a hormone and its target tissue occurs at the receptor, so detection of specific binding sites for somatostatin may help identify potential target tissues for somatostatin, and also may elucidate the mechanism of action of somatostatin.
In a search for specific binding sites for somatostatin, we used ethanol precipitation to separate bound and free somatostatin in particulate fractions (Ogawa et al., 1976) . Subsequently, we discovered that somatostatin was bound to a soluble protein in the cytosol fraction and that ethanol Vol. 165 precipitates soluble binding components in the cytosol fraction.
The present study was designed to identify and characterize a soluble somatostatin-binding protein in cytosol fractions from several tissues.
Materials and Methods
Hormone and drug preparations 910) and [Tyr'] somatostatin, products of Ayerst Research Laboratories, Montreal, Que., Canada, were generously provided by Dr. M. Gotz.
To determine the cross-reactivity, the following hormones were used. Luliberin (luteinizing-hormonereleasing factor) was provided by Ayerst Research Laboratories. [Ala3,Ala14]Somatostatin, somatostatin and a-endorphine were gifts from Dr. R. Guillemin (Salk Institute, La Jolla, CA, U.S.A.). Thyroliberin (thyrotropin-releasing factor) was a gift from Takeda Chemical Industries, Osaka, Japan. [Met] Enkephalin was obtained from Peninsula Laboratories, San Carlos, CA, U.S.A., and Naloxone (N-allyl-nor-oxymorphone hydrochloride) was from Endo Drugs Ltd., Montreal, Que., Canada. Human somatotropin (NIH NS2019G), dog somatotropin (NIH D-1001A), ox somatotropin (NIH B-1003A), pig somatotropin (NIH P-526B), sheep somatotropin (NIH 0-743B), rat somatotropin (NIH RP-1), human prolactin (F-3), sheep prolactin (NIH P-S-10), rat prolactin (NIH RP-1), ox thyrotropin (NIH TSH-B-3), human follitropin (folliclestimulating hormone; NIH LER 1336), human lutropin (luteinizing hormone; NIH LER 960), sheep lutropin (NIH LH-S18) and human placental lactogen were obtained from the National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, MD, U.S.A. Sheep placental lactogen was purified in this laboratory Tables 1 and 3 Lowry et al. (1951) , with bovine serum albumin as standard.
In preliminary experiments, tissues were homogenized in ice-cold 0.3 M-sucrose followed by differential centrifugation as described previously (Shiu et al., 1973; Posner et al., 1974) .
Gelfiltration
Samples were applied to a column (1.2cm x 50 cm) of Sephadex G-100, equilibrated with Tris/EDTA buffer at pH8.0 and 4°C, and 2ml fractions were collected. The column was calibrated with Blue Dextran, 1251-labelled human somatotropin, 1251. labelled [Tyr1]somatostatin and somatostatin, the distribution of the latter being determined by radioimmunoassay (see below). The protein concentration in the fraction was estimated from the A280.
Assays
Iodination. Since somatostatin lacks amino acid residues that can be iodinated, [Tyrl] somatostatin is used for iodination. The biological activity of this analogue is reported to be 107% (Vale et al., 1976) or 100% (Ferland et al., 1976) and 5,u1 of 0.002% H202. After 1 min the reaction was stopped by dilution with 1 ml of ice-cold 2mM-ammonium acetate buffer (pH4.6). The reactants were applied to a column (1cmxlOcm) of CMcellulose equilibrated with the above buffer. Somatostatin was eluted with a continuous gradient (0.002-0.25M) of ammonium acetate buffer at pH4.6. The specific radioactivity of 125I-labelled [Tyr']somatostatin ranged from 80 to 120uCi/ug. Subcellular distribution of somatostatin-binding sites. Initially studies of somatostatin-binding sites were done by methods similar to those described for prolactin (Shiu et al., 1973; Posner et al., 1974) [Tyrl] somatostatin with or without 0.1 ml of a solution (IOug/ml) of somatostatin, and with Tris/EDTA/albumin buffer (50mM-Tris/HCl buffer, pH 8.0, 25 mM-EDTA and 0.5 % bovine serum albumin) in a total volume of 0.5ml. Samples were usually incubated at 4°C for 18h. After the reaction time, 1 ml of chilled dextran-coated charcoal suspension (0.25 % activated charcoal and 0.025 % Dextran T70 in Tris/EDTA/albumin buffer) was added. This binds approx. 98% of free 125I-labelled [Tyr']-somatostatin. Tubes were agitated on a Vortex mixer and left for 30min before centrifugation for 10min at 2000g and 4°C. The supernatant which represents bound hormone was counted in an automatic gamma counter. Specific binding was the difference between radioactivity bound to the somatostatin-binding protein in the presence of excess of somatostatin (1,pg/tube) and that bound in its absence, and was expressed as a percentage of the total radioactivity added per tube.
Effect ofvarious reagents and conditions on binding
Cytosol fractions from female rat liver and bovine anterior pituitaries were used. The effect of pH was studied by exposing cytosol fractions to acetic acid or NaOH (final concentration 0.1 M) for 30min before neutralization. The effect ofethanol was examined by adding cold (4'C) ethanol to a final concentration of 85 % (v/v) and reaction tubes were centrifuged at 2000g for 20min at 4°C. The supernatant was decanted and the pellet dissolved in Tris/EDTA/albumin buffer and assayed. Temperature effects were studied by exposing tissue Vol. 165 cytosols to 56°C for 30min, 100°C for min, or freezing and thawing 20 times (thawing at 20°C for 20min).
Cytosol fractions were incubated at 37'C with various enzymes listed in Table 5 for 15min in the Tris/EDTA/albumin buffer and then chilled in ice. For trypsin digestion, five times as much soyabean trypsin inhibitor as trypsin was added. Cytosol fractions, similarly incubated, but without enzymes, were used as controls.
All samples were adjusted to 40pg of protein per tube before assay.
Dissociation experiments
Cytosol fractions of female rat liver and bovine anterior pituitaries were incubated with 125I-labelled [Tyrl]somatostatin at 4°C for 18 h and then a dextrancoated charcoal suspension was added, followed by centrifugation at 2000g for 10min. To the supernatant (tracer-binding protein complex), 0.1 ml of somatostatin (10,ug/ml) or Tris/EDTA/albumin buffer was added and the dissociation of '251-labelled [Tyrl] somatostatin was examined over 24h.
Cytosol fractions were also incubated with 1251_ labelled [Tyrl]somatostatin for 1.5, 12 or 24h at 4°C and the dextran-coated charcoal suspension was added followed by centrifugation at 2000g for 10min. To the supernatants were added the reagents listed in Table 6 , to give the final concentration indicated, and left for 30min at 24°C. In each case, exposure to the reagent was followed by the addition of 1 ml of dextran-coated charcoal suspension and a second centrifugation at 2000g for 10min. The radioactivity in the second pellet (free tracer) was counted on an automatic gamma-counter.
Radioimmunoassay ofsomatostatin
To each assay tube was added 0.2 ml of the buffer used for binding assays, 0.1 ml of anti-somatostatin rabbit serum (1:4000 dilution) prepared by the authors (Epelbaum et al., 1977) , 0.1ml of somatostatin solution in concentrations from lOpg/ml to lOOng/ml, or samples, and 0.1ml of 125I-labelled [Tyrllsomatostatin (15000-20000c.p.m.) . This reaction mixture was incubated at 4°C for 48h, then 0.1 ml of 5% sheep anti-(rabbit y-globulin) serum and 0.1 ml of 1 % normal rabbit serum were added and the mixture was incubated for 24h at 4°C. The tubes were then centrifuged at 2000g for 30min, decanted and the pellet counted for radioactivity on an automatic gamma counter.
Results Subcellular binding sites for somatostatin Table 1 indicates considerable somatostatinbinding activity in the various pellets of female rat somatostatin (10,g/ml), each in a total volume of 7.5ml, for 4h in ice. A portion (0.Sml) of the reaction mixture was used for the determination of specific binding by using ethanol to precipitate bound somatostatin (EtOH method) as described in the Materials and Methods section (Step I). The remainder of the reaction mixture in both cases was centrifuged at 200000g for 60min and the radioactivity in both pellets was counted (Step II). To determine the specific binding of the 200000g supernatant 0.5ml of each supernatant from Step II was treated by the EtOH method or the dextrancoated charcoal method as described in the Materials and Methods section (Step III).
Step I
Step tissues. Table 2 indicates that most somatostatinbinding activity occurs in the 200000g supernatant (cytosol fraction) of rat liver. Most of the binding activity in the 100000g pellet can be detected in the supernatant after resuspension of the pellet (Table 2) . Similar results were obtained with rat submandibular-gland subcellular fractions.
Effect ofEDTA and Ca2+
Three different 5OmM-Tris/HCI buffers at pH8.0 containing 25mM-EDTA, no EDTA, or without EDTA but with 1 mM-CaCI2, were used for homogenization and incubation. Rat liver cytosol proteins (100pg per tube) were incubated in ice for 5h. With 25mM-EDTA, the specific binding is 25.8± 2.4% (mean±s.E.M., n = 5). Without EDTA, it is 15.2±1.4% (n=3) and with lmM-CaCl2 it is decreased to 4.4±0.4 % (n = 3).
Optimum conditions for assay ofbinding activity
The specific binding was maximum after 12-24h incubation at 4°C for all tissues (Fig. 1) (Fig. 2) . The pH optima for specific binding is pH 8.0-8.5 in all tissues (Fig. 3) . The tissues with somatostatin-binding sites in the cytosol are listed in Table 3 . Effects ofenzymes on somatostatin-binding activity Table 5 shows the effect of incubation of cytosol fraction containing somatostatin-binding activity with various enzymes. Binding activity is decreased K Dissociation studies Excess of unlabelled somatostatin is unable to displace 125I-labelled [Tyrl] somatostatin previously bound to somatostatin-binding protein (results not shown). Dithiothreitol and mercaptoethanol enhance dissociation the most, and their effect increases with prolonged periods of preincubation for the binding between the binding protein and the tracer (Table 6 ). Urea and guanidine hydrochloride dissociate tracer binding somewhat, but increasing preincubation time decreases their ability to do so. Spontaneous dissociation (control) also decreases with increasing preincubation time.
Comparison of somatostatin-binding protein from various sources
Two distinct peaks of radioactivity were noted after gel filtration on Sephadex G-100 of supernatants obtained as described in the legend to Fig. 4 . The largest peak (fractions 12-16) appeared just after the void volume, and the second smaller peak was coincident with somatostatin and 125I-labelled [Tyr1]-somatostatin. Gel filtration on Sephadex G-100 of cytosol from a variety of rat tissues yielded similar elution volumes for somatostatin-binding activity (Figs. 5a and 5b) these tissues, the major somatostatin-binding peak in all cases was found in gel segments at pH4.6-4.9
(results not shown).
Specificity of the somatostatin-binding protein By using rat anterior-pituitary cytosol samples, semi-purified by gel filtration on Sephadex G-100, the specificity of the somatostatin-binding protein was determined (Fig. 6 ). Significant inhibition of the binding occurred with 300pg of somatostatin. somatostatin crossreacted 150 and 40% respectively. [Ala3,Ala'4]-Somatostatin, a linear analogue, was only 10 % cross-reactive. Surprisingly, pig glucagon and synthetic corticotropin were 7 and 5 % cross-reactive respectively. All other hormones tested were less than 1 % as active. Similar specificity was obtained with the semi-purified binding protein from rat liver cytosol.
Effects of the somatostatin-binding protein on the radioimmunoassay ofsomatostatin Fig. 5 shows that somatostatin-binding protein decreases binding of somatostatin to anti-somatostatin serum. Fig. 7 shows that as little as 1 ug of somatostatin-binding protein from various tissues decreases the binding of 125I-labelled
[Tyrt]somatostatin to anti-somatostatin serum.
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Discussion
The present study demonstrates that somatostatin binds to macromolecules with mol.wt. 80000, found in the cytosol fraction (200000g supernatant) of various rat, human and bovine tissues (Figs. 4 and 5 and Table 3 ). As specific binding of somatostatin to plasma and peripheral blood cell cytosol is low, it is unlikely that the specific binding of the cytosol fraction is due to contamination by blood elements. The fact that trypsin, but not RNAase and DNAase, destroyed the somatostatinbinding activity, suggests that this somatostatinbinding factor is protein in nature.
This binding protein is not completely somatostatin-specific, and the relative potency of somatostatin analogues (Fig. 6 ) is somewhat different from bioassay results Vale et al., 1975 Vale et al., , 1976 Ferland et al., 1976) .
Dissociation studies ( Whether this somatostatin-binding protein is a true receptor for somatostatin is unknown. There may be a plasma-membrane receptor for somatostatin, because significant binding (approx. 20 % of that found on the cytosol) of somatostatin to particulate fractions was still noted after resuspension followed by centrifugation (Table 2) . It is also possible that the somatostatin-binding protein is an easily solubilized membrane protein. This would explain why residual binding in the 1000OOg pellet is so easily solubilized on resuspension (Table 2) .
There is evidence that the site of action of somatostatin is distal to cyclic AMP synthesis (Borgeat et al., 1974; Gerich et al., 1975) . Moreover melanotropin (Varga et al., 1976) and prolactin (Posner & Bergeron, 1976) (Table 4) commonly used for extracting somatostatin, estimates of somatostatin in such extracts by radioimmunoassay in some cases will be inaccurate.
